Organovo

Organovo is a Biotechnology company based in India. Founded in 2007, it employs 24 people and generates over $10,000 in annual revenue. Organovo is pioneering a unique set of therapeutic and drug profiling capabilities. Organovo specializes in 3D bioprinting tissues that mimic human biology and disease. Their business model revolves around developing novel therapies for diseases using human primary cell 3D models. Organovo targets pharmaceutical companies and research institutions involved in drug discovery and development. Organovo's technology has the potential to revolutionize drug discovery by creating more accurate and reliable models of human disease. Their 3D bioprinted tissues offer a more realistic representation of disease processes compared to traditional methods. Contact Organovo at www.organovo.com.

Organovo Holdings Inc. is a biotechnology company specializing in the rapid clinical and commercial development of new medicines. The company utilizes 3D human tissue model technology. Organovo is located at 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121. The company's phone number is +18582241000. Organovo's primary focus is on creating human models of diseases, including inflammatory bowel disease (IBD), to facilitate the development of drug therapies. Their lead therapeutic molecule, FXR314, is currently in Phase 2 clinical trials for ulcerative colitis. Organovo operates within the healthcare, pharmaceuticals, and biotechnology industries. Organovo leverages 3D human tissue models for drug discovery. They utilize pioneering 3D bioprinting technology. The company's competitive advantages include these technologies and a highly experienced leadership team. Organovo's leadership includes Executive Chairman Keith Murphy, Chief Financial Officer Norman Staskey, and Senior Vice President, Strategy and Business Development Curtis Tyree, Ph.D. The company is committed to innovation and advancing drug discovery. They focus on human primary cell 3D models. Organovo's values include innovation and a commitment to advancing drug discovery.